Immunobiology of Critical Pediatric Asthma

Clinical Reviews in Allergy and Immunology

Volumn 48, Issue 1, 2015, Pages 84-96

  Galowitz, Stacey ^a,b   Chang, Christopher ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Airway epithelial cells; Asthma phenotypes; Biological response modifier therapy; Dendritic cells; Eosinophilic asthma; Eosinophils; Immunotherapy; Innate immunity; Leukotrienes; Prostaglandins; Severe asthma; T helper cells; TH2 cells; Thymic stromal lymphopoietin; Toll like receptors; Vitamin D

Indexed keywords

CYTOKINE; LEUKOTRIENE; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ANIMAL; ASTHMA; CHILD; CRITICAL ILLNESS; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; MOLECULARLY TARGETED THERAPY; RESPIRATORY TRACT MUCOSA; RISK FACTOR; TH17 CELL; TH2 CELL;

ADAPTIVE IMMUNITY; ANIMALS; ASTHMA; CHILD; CRITICAL ILLNESS; CYTOKINES; HUMANS; IMMUNITY, INNATE; LEUKOTRIENES; MOLECULAR TARGETED THERAPY; RESPIRATORY MUCOSA; RISK FACTORS; TH17 CELLS; TH2 CELLS; TOLL-LIKE RECEPTORS;

EID: 84892579068     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-014-8409-z     Document Type: Review

References (139)

1. Yoo Y (2013) Phenotypes and endotypes of severe asthma in children. Korean J Pediatr 56(5):191–5
2. Moore WC et al (2007) Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol 119(2):405–13
3. Spycher BD, Silverman M, Kuehni CE (2010) Phenotypes of childhood asthma: are they real? Clin Exp Allergy 40(8):1130–41
4. Tseng W, Sutter ME, Albertson TE (2013) Stimulants and the lung: review of literature. Clin Rev Allergy Immunol. doi:10.1007/s12016-013-8376-9
5. Klimek L, Pfaar O (2013) A comparison of immunotherapy delivery methods for allergen immunotherapy. Expert Rev Clin Immunol 9(5):465–74, quiz 475
6. Chang C (2012) Asthma in children and adolescents: a comprehensive approach to diagnosis and management. Clin Rev Allergy Immunol 43(1–2):98–137
7. Matucci A et al (2012) Asthma: developments in targeted therapy. Expert Rev Clin Immunol 8(1):13–5
8. Vatti RR, Teuber SS (2012) Asthma and pregnancy. Clin Rev Allergy Immunol 43(1–2):45–56
9. Louie S et al (2012) The critically ill asthmatic—from ICU to discharge. Clin Rev Allergy Immunol 43(1–2):30–44
10. Leong AB, Ramsey CD, Celedon JC (2012) The challenge of asthma in minority populations. Clin Rev Allergy Immunol 43(1–2):156–83
11. Chan A L et al (2013) Management of critical asthma syndrome during pregnancy. Clin Rev Allergy Immunol. doi:10.1007/s12016-013-8397-4
12. Schivo M et al (2013) Critical asthma syndrome in the ICU. Clin Rev Allergy Immunol. doi:10.1007/s12016-013-8394-7
13. Kenyon N et al (2013) Definition of Critical Asthma Syndromes. Clin Rev Allergy Immunol. doi:10.1007/s12016-013-8395-6
14. Siroux V, Garcia-Aymerich J (2011) The investigation of asthma phenotypes. Curr Opin Allergy Clin Immunol 11(5):393–9
15. Anderson GP (2008) Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 372(9643):1107–19
16. Lotvall J et al (2011) Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 127(2):355–60
17. Wenzel S (2012) Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 42(5):650–8
18. Kim HY, DeKruyff RH, Umetsu DT (2010) The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol 11(7):577–84
19. Lambrecht BN, Hammad H (2012) The airway epithelium in asthma. Nat Med 18(5):684–92
20. Bailey M, Christoforidou Z, Lewis M (2013) Evolution of immune systems: specificity and autoreactivity. Autoimmun Rev 12(6):643–7
21. Hammad H et al (2009) House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med 15(4):410–6
22. Trompette A et al (2009) Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature 457(7229):585–8
23. Pace E et al (2008) Cigarette smoke increases Toll-like receptor 4 and modifies lipopolysaccharide-mediated responses in airway epithelial cells. Immunology 124(3):401–11
24. Monick MM et al (2003) Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem 278(52):53035–44
25. Saenz SA et al (2010) IL25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. Nature 464(7293):1362–6
26. Neill DR et al (2010) Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464(7293):1367–70
27. Fort MM et al (2001) IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15(6):985–95
28. Schneider E et al (2009) IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J Immunol 183(6):3591–7
29. Aderem A, Ulevitch RJ (2000) Toll-like receptors in the induction of the innate immune response. Nature 406(6797):782–7
30. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388(6640):394–7
31. Muzio M et al (2000) Toll-like receptor family and signalling pathway. Biochem Soc Trans 28(5):563–6
32. Dabbagh K et al (2002) Toll-like receptor 4 is required for optimal development of Th2 immune responses: role of dendritic cells. J Immunol 168(9):4524–30
33. Gern JE (2000) Viral and bacterial infections in the development and progression of asthma. J Allergy Clin Immunol 105(2 Pt 2):S497–502
34. Kurt-Jones EA et al (2000) Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1(5):398–401
35. Gill MA (2012) The role of dendritic cells in asthma. J Allergy Clin Immunol 129(4):889–901
36. Zhang Q et al (2011) Polymorphisms in toll-like receptor 4 gene are associated with asthma severity but not susceptibility in a Chinese Han population. J investig allergol Clin Immunol 21(5):370–7
37. Sackesen C et al (2005) The effect of polymorphisms at the CD14 promoter and the TLR4 gene on asthma phenotypes in Turkish children with asthma. Allergy 60(12):1485–92
38. Beeh KM et al (2013) The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol 131(3):866–74
39. Haldar P, Pavord ID (2007) Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J Allergy Clin Immunol 119(5):1043–52, quiz 1053–4
40. Wardlaw AJ et al (1988) Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. Am Rev Respir Dis 137(1):62–9
41. Bousquet J et al (1990) Eosinophilic inflammation in asthma. N Engl J Med 323(15):1033–9
42. Bentley AM et al (1996) Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med 153(2):551–6
43. Beasley R et al (1989) Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 139(3):806–17
44. Gibson PG, Fujimura M, Niimi A (2002) Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax 57(2):178–82
45. Payne DN et al (2001) Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med 164(8 Pt 1):1376–81
46. Baraldi E, Zanconato S (2001) The labyrinth of asthma phenotypes and exhaled NO. Thorax 56(5):333–5
47. Dweik RA et al (2011) An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 184(5):602–15
48. Fahy JV (2009) Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc Am Thorac Soc 6(3):256–9
49. Woodruff PG et al (2001) Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol 108(5):753–8
50. Wenzel SE et al (1997) Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 156(3 Pt 1):737–43
51. Wenzel SE et al (1999) Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 160(3):1001–8
52. Gibson PG, Simpson JL, Saltos N (2001) Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 119(5):1329–36
53. Berry M et al (2007) Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 62(12):1043–9
54. Green RH et al (2002) Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360(9347):1715–21
55. Jayaram L et al (2006) Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 27(3):483–94
56. Brown HM (1958) Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. Lancet 2(7059):1245–7
57. Pavord ID et al (1999) Non-eosinophilic corticosteroid unresponsive asthma. Lancet 353(9171):2213–4
58. van Rijt LS et al (2002) Allergen-induced accumulation of airway dendritic cells is supported by an increase in CD31(hi)Ly-6C(neg) bone marrow precursors in a mouse model of asthma. Blood 100(10):3663–71
59. Lambrecht BN et al (1999) Allergen-induced changes in bone-marrow progenitor and airway dendritic cells in sensitized rats. Am J Respir Cell Mol Biol 20(6):1165–74
60. Lambrecht BN et al (2000) Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest 106(4):551–9
61. Sung S, Rose CE, Fu SM (2001) Intratracheal priming with ovalbumin- and ovalbumin 323–339 peptide-pulsed dendritic cells induces airway hyperresponsiveness, lung eosinophilia, goblet cell hyperplasia, and inflammation. J Immunol 166(2):1261–71
62. Liu YJ (2005) IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23:275–306
63. Gill MA et al (2010) Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells. J Immunol 184(11):5999–6006
64. Gehlhar K et al (2006) Impaired virus-induced interferon-alpha2 release in adult asthmatic patients. Clin Exp Allergy 36(3):331–7
65. Bufe A et al (2002) Atopic phenotype in children is associated with decreased virus-induced interferon-alpha release. Int Arch Allergy Immunol 127(1):82–8
66. Huber JP et al (2010) Cutting edge: type I IFN reverses human Th2 commitment and stability by suppressing GATA3. J Immunol 185(2):813–7
67. Moschen AR et al (2008) Interferon-alpha controls IL-17 expression in vitro and in vivo. Immunobiology 213(9–10):779–87
68. Harrington LE et al (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6(11):1123–32
69. Allakhverdi Z et al (2007) Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 204(2):253–8
70. Liu YJ et al (2007) TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol 25:193–219
71. Ying S et al (2005) Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol 174(12):8183–90
72. Zhou B et al (2005) Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol 6(10):1047–53
73. Fang C et al (2010) The role of thymic stromal lymphopoietin in allergic inflammation and chronic obstructive pulmonary disease. Arch Immunol Ther Exp (Warsz) 58(2):81–90
74. Tu HY, Chen X, Li J (2007) [Signal transduction in respiratory syncytial virus infection-induced thymic stromal lymphopoietin expression in human epithelial cells]. Nan Fang Yi Ke Da Xue Xue Bao 27(10):1581–3
75. Robinson DS et al (1992) Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 326(5):298–304
76. Steinke JW, Borish L (2001) Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res 2(2):66–70
77. Greenfeder S et al (2001) Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res 2(2):71–9
78. Levitt RC et al (1999) IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. J Allergy Clin Immunol 103(5 Pt 2):S485–91
79. Eklund KK et al (1993) Induction by IL-9 and suppression by IL-3 and IL-4 of the levels of chromosome 14-derived transcripts that encode late-expressed mouse mast cell proteases. J Immunol 151(8):4266–73
80. Louahed J et al (1995) IL-9 induces expression of granzymes and high-affinity IgE receptor in murine T helper clones. J Immunol 154(10):5061–70
81. Hultner L, Moeller J (1990) Mast cell growth-enhancing activity (MEA) stimulates interleukin 6 production in a mouse bone marrow-derived mast cell line and a malignant subline. Exp Hematol 18(8):873–7
82. Dugas B et al (1993) Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. Eur J Immunol 23(7):1687–92
83. Petit-Frere C et al (1993) Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes. Immunology 79(1):146–51
84. Sears MR et al (1991) Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 325(15):1067–71
85. Wills-Karp M et al (1998) Interleukin-13: central mediator of allergic asthma. Science 282(5397):2258–61
86. Grunig G et al (1998) Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282(5397):2261–3
87. Pope SM et al (2001) IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J Allergy Clin Immunol 108(4):594–601
88. Martinez-Nunez RT, Louafi F, Sanchez-Elsner T (2011) The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). J Biol Chem 286(3):1786–94
89. Ramirez-Icaza G et al (2004) Th2 cytokines IL-4 and IL-13 downregulate paxillin expression in bronchial airway epithelial cells. J Clin Immunol 24(4):426–34
90. Zhu Z et al (1999) Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 103(6):779–88
91. Chibana K et al (2008) IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy 38(6):936–46
92. Kuperman DA et al (2002) Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 8(8):885–9
93. Angkasekwinai P et al (2007) Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med 204(7):1509–17
94. Dolgachev V et al (2009) Pulmonary IL-17E (IL-25) production and IL-17RB + myeloid cell-derived Th2 cytokine production are dependent upon stem cell factor-induced responses during chronic allergic pulmonary disease. J Immunol 183(9):5705–15
95. Tamachi T et al (2006) IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice. J Allergy Clin Immunol 118(3):606–14
96. Ballantyne SJ et al (2007) Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 120(6):1324–31
97. Liew FY, Pitman NI, McInnes IB (2010) Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 10(2):103–10
98. Silver MR et al (2010) IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res 59(3):207–18
99. Cherry WB et al (2008) A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 121(6):1484–90
100. Kearley J et al (2009) Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 179(9):772–81
101. Kurowska-Stolarska M et al (2009) IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 183(10):6469–77
102. Coyle AJ et al (1999) Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 190(7):895–902
103. Liu X et al (2009) Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun 386(1):181–5
104. Barczyk A, Pierzchala W, Sozanska E (2003) Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med 97(6):726–33
105. Wilson RH et al (2009) Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness. Am J Respir Crit Care Med 180(8):720–30
106. Dias PM, Banerjee G (2013) The role of Th17/IL-17 on eosinophilic inflammation. J Autoimmun 40:9–20
107. Nakae S et al (2002) Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17(3):375–87
108. Pichavant M et al (2008) Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. J Exp Med 205(2):385–93
109. Schroeder JT et al (2010) Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol 125(4):896–901 e6
110. Antico A et al (2012) Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 12(2):127–36
111. Litonjua AA (2012) Vitamin D deficiency as a risk factor for childhood allergic disease and asthma. Curr Opin Allergy Clin Immunol 12(2):179–85
112. Beard JA, Bearden A, Striker R (2011) Vitamin D and the anti-viral state. J Clin Virol 50(3):194–200
113. Litonjua AA (2009) Childhood asthma may be a consequence of vitamin D deficiency. Curr Opin Allergy Clin Immunol 9(3):202–7
114. Brehm JM et al (2010) Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. J Allergy Clin Immunol 126(1):52–8 e5
115. Freishtat RJ et al (2010) High prevalence of vitamin D deficiency among inner-city African American youth with asthma in Washington, DC. J Pediatr 156(6):948–52
116. Bener A et al (2012) Vitamin D deficiency as a strong predictor of asthma in children. Int Arch Allergy Immunol 157(2):168–75
117. Alyasin S et al (2011) The relationship between serum 25 hydroxy vitamin d levels and asthma in children. Allergy Asthma Immunol Res 3(4):251–5
118. Keet CA et al (2011) Age- and atopy-dependent effects of vitamin D on wheeze and asthma. J Allergy Clin Immunol 128(2):414–16 e5
119. van Oeffelen AA et al (2011) Serum micronutrient concentrations and childhood asthma: the PIAMA birth cohort study. Pediatr Allergy Immunol 22(8):784–93
120. Jonuleit H et al (2000) Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192(9):1213–22
121. Akbari O, DeKruyff RH, Umetsu DT (2001) Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2(8):725–31
122. Akdis CA et al (1998) Role of interleukin 10 in specific immunotherapy. J Clin Invest 102(1):98–106
123. Nouri-Aria KT et al (2004) Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 172(5):3252–9
124. Varney VA et al (1993) Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 92(2):644–51
125. Secrist H et al (1993) Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 178(6):2123–30
126. Ebner C et al (1997) Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 27(9):1007–15
127. Mothes N et al (2003) Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 33(9):1198–208
128. Visco V et al (1996) Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J Immunol 157(2):956–62
129. Moller C et al (2002) Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 109(2):251–6
130. Almomani B et al (2013) Can certain genotypes predispose to poor asthma control in children? A pharmacogenetic study of 9 candidate genes in children with difficult asthma. PloS one 8(4):e60592
131. Burchard EG et al (1999) Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma. Am J Respir Crit Care Med 160(3):919–22
132. Sandford AJ et al (2000) Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity. J Allergy Clin Immunol 106(1 Pt 1):135–40
133. Tantisira KG et al (2004) Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Human Mol Genet 13(13):1353–9
134. Berry MA et al (2006) Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 354(7):697–708
135. Bradding P et al (1994) Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 10(5):471–80
136. Holgate ST et al (2009) The role of the airway epithelium and its interaction with environmental factors in asthma pathogenesis. Proc Am Thorac Soc 6(8):655–9
137. Figueiredo CA et al (2012) Does IFN-gamma play a role on the pathogenesis of non-atopic asthma in Latin America children? Allergy Asthma Clin Immunol 8(1):18
138. Palmer CN et al (2007) Filaggrin null mutations are associated with increased asthma severity in children and young adults. J Allergy Clin Immunol 120(1):64–8
139. Leung TF et al (2003) The C-159T polymorphism in the CD14 promoter is associated with serum total IgE concentration in atopic Chinese children. Pediatr Allergy Immunol 14(4):255–60